What Scailyte does

Scailyte AG is a Basel-based precision medicine company that operates the ScaiVision™ analytics platform, which applies proprietary Supervised Representation Learning and Deep Generative/Single-Cell Foundation Models to large-scale single-cell and spatial omics datasets matched with longitudinal clinical outcomes. The platform's core output is the identification of disease-driving cellular states and high-resolution patient endotypes that translate into predictive biomarkers, responder signatures, and Companion Diagnostics (CDx) candidates. Its flagship commercial program is the IBD Flagship, anchored by an exclusive data partnership with the Swiss IBD Cohort (4,000+ patients, 15+ years of longitudinal data, 40,000+ samples) — the largest tissue single-cell omics IBD Atlas the company has publicly described.

The company is organized around three partnership offerings for pharmaceutical and biotech clients: (1) asset de-risking and trial stratification via in silico validation using the IBD Foundation Model, (2) target discovery and combination positioning using deep spatial-omics, and (3) co-development of predictive biomarkers as Companion Diagnostics. Additional internal validation projects — including an NK Cell Therapy manufacturing QC marker and a CTCL blood-based diagnostic achieving 97 percent accuracy — demonstrate platform breadth beyond IBD. The company holds a pending diagnostic patent (EP19219889) and has executed its first named commercialization partnership (Hera Biotech) for an endometrial tissue-based diagnostic.

Commercially, Scailyte generates revenue through negotiated B2B enterprise partnerships with pharmaceutical companies, structured as licensing/royalty arrangements for pharma agreements and professional services / milestone-based payments for Companion Diagnostics co-development. Pricing is quote-based and not publicly disclosed. The company is privately held and venture-backed, having raised approximately CHF 6 million in Series A funding in September 2022 (Mirabaud, Swisscom Ventures) plus a follow-on round in December 2023, on top of earlier rounds led by Swisscom Ventures, Hemex, 4FOX Ventures, Verve Ventures, MassChallenge, Innos Suisse, and Venture Kick since 2017.

Name

Scailyte

Legal name

Scailyte AG

Website

https://scailyte.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Scailyte AG is a Basel-based precision medicine company whose ScaiVision™ platform applies proprietary AI to single-cell and spatial omics data, generating patient endotypes, biomarkers, and companion diagnostics for pharmaceutical partners in autoimmune disease (notably IBD) and immuno-oncology.

Ownership category

akta.pro rank

Product category

Precision Medicine AI Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Single-cell omics
• Precision medicine AI
• Biomarker discovery
• Patient endotyping
• Autoimmune disease research

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharma Partnership Agreements: Scailyte generates revenue through strategic partnerships with pharmaceutical companies, offering services including asset de-risking, trial stratification, target discovery, and precision diagnostics co-development. Revenue is likely generated through milestone-based payments, licensing fees, and potentially royalty arrangements on successfully commercialized diagnostics.
2. Companion Diagnostics (CDx) Development: Co-development of predictive biomarkers as Companion Diagnostics with pharma partners, potentially generating revenue through development fees, regulatory milestones, and commercialization royalties.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Scailyte develops and operates ScaiVision, an AI-powered analytics platform that combines large-scale single-cell and spatial omics data with longitudinal clinical outcomes to identify disease-driving cellular states. The platform supports pharma partnerships across asset de-risking, trial stratification, target discovery, and co-development of companion diagnostics, with a primary focus on autoimmune diseases such as Inflammatory Bowel Disease (IBD).

Product overview

Scailyte is a precision medicine company offering ScaiVision™, an AI-powered analytics platform built on proprietary Supervised Representation Learning and Deep Generative/Single-Cell Foundation Models. The platform processes large-scale single-cell and spatial omics data combined with longitudinal clinical outcomes to identify disease-driving cellular states and enable patient endotyping. The IBD Flagship Program represents the company's disease-specific application of this technology for Inflammatory Bowel Disease, while additional internal projects demonstrate capabilities in tissue-based and blood-based diagnostics for pharmaceutical and diagnostic partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• ScaiVision: Proprietary AI-powered analytics platform using Supervised Representation Learning for biomarker discovery and patient endotyping from single-cell and spatial omics data.

Products and services

• ScaiVision AI-powered analytics platform that integrates multimodal single-cell and spatial omics data with longitudinal clinical outcomes to identify disease-driving cellular states and generate predictive, translatable models for diagnostics and therapeutics. It is offered to pharmaceutical partners for asset de-risking, trial stratification, target discovery, and companion diagnostic co-development in autoimmune and immuno-oncology indications.
• IBD Flagship Program Strategic disease-focused application of the ScaiVision platform targeting Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease), offering pharma partners in silico validation, high-resolution patient endotyping, responder signature identification, and biomarker assay development for clinical trial design and precision therapeutics.
• Companion Diagnostics (CDx) Co-Development Service offering for pharmaceutical partners to co-develop predictive biomarker assays as Companion Diagnostics, translating ScaiVision-derived molecular signatures into clinically validated tests that ensure high response rates and clinical differentiation for partnered therapeutics.

Quantifiable outcome

• >90% specificity achieved with first-in-kind tissue-based molecular diagnostic
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• Hera BiotechcoreOEM/ Whitelabel/ Licensing PartnerStrategic partnership for global commercialization of Scailyte's first-in-kind tissue-based molecular diagnostic. Scailyte discovered unique molecular signatures in endometrial tissue that correlate with active lesions, achieving >90% specificity, and partnered this asset to Hera Biotech for worldwide commercialization.
• Swiss IBD CohortcoreStrategic or Co-development PartnerExclusive clinical data partnership providing access to 4,000+ IBD patients with 15+ years of longitudinal data and 40,000+ samples. This partnership anchors Scailyte's IBD Flagship Program and provides the foundational data for training AI models and disease modeling.
• Key Opinion Leaders (KOLs) NetworkcoreStrategic or Co-development PartnerNetwork of leading key opinion leaders providing clinical samples and data from longitudinal national cohorts in IBD and other autoimmune diseases. Supports the company's discovery platform and AI model validation.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• CytoReason: CytoReason is an AI platform that builds cell-level models of the immune system for pharma R&D, including patient stratification and target discovery in autoimmune and inflammatory disease. Closest direct peer to Scailyte given the overlap in single-cell/immune modeling, pharma partnership GTM, and disease focus on IBD and immunology.
• Owkin: Owkin applies AI to multi-modal patient data to support pharma with target discovery, trial optimization, and companion diagnostics across oncology and immunology. Comparable enterprise sales motion, multi-modal foundation model approach, and pharma partnership revenue model.
• Insitro: Insitro combines machine learning with high-throughput biology to discover and develop therapeutics, with a partnership model with pharma. Similar AI-first platform positioning for drug discovery, though Insitro is more development-stage and vertically integrated into therapeutics.
• GNS (GNS Healthcare): GNS applies causal AI to multi-modal patient data to support pharma with patient stratification, trial enrichment, and biomarker discovery. Comparable in the precision-medicine AI-for-pharma value proposition and partnership-driven GTM.
• Adaptive Biotechnologies: Adaptive uses immune repertoire sequencing and single-cell immune profiling to develop diagnostics and partner with pharma on antigen discovery and immune monitoring. Direct overlap with Scailyte's single-cell immune profiling approach and pharma CDx partnership motion.

Broad incumbents

• Tempus Labs: Tempus is a large precision medicine data and AI platform that partners with pharma on biomarker discovery, CDx, and real-world evidence. Significantly larger scale and broader data library (multiomics plus clinical), serving as a broad incumbent in the same enterprise pharma AI category.
• Recursion Pharmaceuticals: Recursion combines high-throughput biology with foundation models and AI to discover therapeutics at scale. Overlaps in AI-driven pharma R&D and foundation model narrative, but operates at a much larger scale and is more therapeutics-focused rather than a partnership/CDx platform.
• Benevolent AI: Benevolent AI applies foundation models to biomedical knowledge graphs to identify novel targets and support pharma R&D decisions. Comparable in AI-for-pharma R&D positioning and partnership-led model, though more knowledge-graph-based than single-cell-omics-based.
• Schrödinger: Schrödinger provides computational chemistry and biology software plus a partnered therapeutics pipeline, working with pharma on target identification and lead optimization. Broad incumbent in AI/computation-enabled pharma R&D with a software-plus-partnerships model.

Others

• 10x Genomics: 10x Genomics is the dominant provider of single-cell and spatial omics instrumentation and software used by pharma and academic labs. Ecosystem/supplier relationship to Scailyte, which depends on 10x platforms (or similar) for generating the single-cell data that feeds ScaiVision.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@scailyte
• LinkedInlinkedin.com/company/scailyte

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scailyte